Mosquitoes, though small, pose a massive threat, spreading viruses like Chikungunya, Dengue, West Nile, Yellow Fever, Zika, and Japanese Encephalitis that afflict millions worldwide. Fueled by climate change, urban growth, and global travel, these pathogens are spreading faster than ever, making the need for advanced diagnostics, treatments, and vaccines more urgent. This article explores how these viruses work, the challenges in controlling them, and the lab tools helping scientists fight back.
Fig. 1. Where mosquito-borne diseases are hitting hardest (Higuera & Ramírez, 2019).
Major Mosquito-Borne Diseases
Chikungunya: Beyond the Fever—Unraveling a Debilitating Threat
Chikungunya virus (CHIKV), a member of the Alphavirus genus within the Togaviridae family, is primarily transmitted by Aedes aegypti and Aedes albopictus mosquitoes. The name “Chikungunya” comes from a Makonde word meaning “that which bends up,” referring to the severe joint pain that can leave patients stooped or immobile for weeks to months. Originally identified in Africa in 1952, CHIKV has rapidly expanded its geographic range, with significant outbreaks reported across Asia, Europe, and the Americas in the past two decades. Climate change, global travel, and mosquito adaptation are accelerating its spread, making it a growing global threat.
Fig. 2. Structural diagram of Chikungunya virus (viralzone).
| Catalog No. | Product Name | Applications |
|---|---|---|
| VK572013 | Anti-CHIKV Spike glycoprotein E2 Antibody (CHK265) | ELISA, FCM, Neutralization |
| VK425014 | Anti-CHIKV Spike glycoprotein E1 Polyclonal Antibody | WB, IHC, ELISA |
| VK640012 | Recombinant CHIKV NSP2 Protein, N-GST-His | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| VK572011 | Recombinant CHIKV Spike glycoprotein E2 Protein, C-Fc | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| VK425063 | Anti-CHIKV p130/Structural polyprotein Antibody (DC1.55) | ELISA, FCM |
How It Works
- E1/E2 Spike Glycoproteins: These proteins latch onto host cells, sparking infection and making them key targets for vaccines.
- nsP2 Protein: Fuels viral RNA replication while dodging the body’s antiviral defenses.
- nsP4 Protein: Drives RNA polymerase activity, linked to the chronic joint pain that plagues patients.
Dengue: Four Serotypes, One Complex Challenge
Dengue virus (DENV), part of the Flaviviridae family, includes four antigenically distinct serotypes (DENV-1 to DENV-4). It is transmitted mainly by Aedes mosquitoes and can lead to a spectrum of disease, from mild febrile illness to life-threatening Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS). The phenomenon of antibody-dependent enhancement (ADE) makes secondary infections more dangerous. Dengue affects an estimated 100–400 million people annually, thriving in tropical and subtropical regions, with urbanization and climate factors expanding its reach.
Fig. 3. Structural diagram of Dengue virus (10.3390/immuno4040033).
| Catalog No. | Product Name | Applications |
|---|---|---|
| VK563013 | Anti-DENV-2 NS1 Antibody (DENV2P10) | ELISA, SPR |
| VK589064 | Anti-DENV-2 Envelope protein E Polyclonal Antibody | ELISA, IHC, WB |
| VK563021 | Recombinant DENV-2 NS1 Protein, C-His | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| VK589040 | InVivoMAb Anti-DENV-2 Envelope protein E/EDIII domain Antibody (3H5) | DB, Neutralization, RIA, SPR |
| VK494012 | Recombinant DENV-1 Protein prM/prM Protein, N-GST & C-His | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
How It Works
- Envelope (E) Protein: Drives viral entry into cells but can worsen infections through ADE, complicating vaccine design.
- NS1 Protein: Triggers blood vessel damage in severe cases and serves as a key marker for diagnostics.
- NS3/NS5 Proteins: Power viral replication and block immune responses, fueling infection.
West Nile Virus: A Silent Invader With Neurotropic Potential
West Nile Virus (WNV), also a flavivirus, is carried by Culex mosquitoes and maintains its cycle through bird reservoirs. While most infections are asymptomatic, a small percentage develop neuroinvasive disease—especially in the elderly and immunocompromised. WNV is endemic in Africa, has become entrenched in Europe and North America, and continues to expand due to migratory birds and climate shifts.
Fig. 4. Structural diagram of West Nile virus (npj Viruses volume 3, Article number: 36 (2025)).
| Catalog No. | Product Name | Applications |
|---|---|---|
| VK554014 | Anti-West Nile Virus NS1 Polyclonal Antibody | ELISA, IHC, WB |
| VK554023 | Anti-West Nile Virus GP1/Genome polyprotein Antibody (CR4374) | ELISA, SPR, WB |
| VK554012 | Recombinant West Nile Virus NS1 Protein, N-His | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| VK554021 | Recombinant West Nile Virus NS1 Protein, C-Fc | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| VK554013 | Anti-West Nile Virus GP1/Genome polyprotein Antibody (CR4353) | ELISA, SPR, WB |
How It Works
- Envelope (E) Protein: Enables viral entry into cells, serving as a prime target for neutralizing antibodies.
- NS1 Protein: May weaken the blood-brain barrier, contributing to neurological damage.
- NS3/NS5 Proteins: Drive replication and help the virus evade immune defenses.
Yellow Fever: Ancient Foe, Ongoing Challenge
Yellow Fever Virus (YFV) is one of the most historically significant arboviruses. Transmitted by Aedes mosquitoes, it can cause a wide range of symptoms—from mild fever to severe hepatic injury, jaundice, and hemorrhagic manifestations. Despite the availability of an effective live-attenuated vaccine, logistical barriers and vaccine hesitancy have hampered global immunization efforts, especially in outbreak-prone regions of Africa and South America.
Fig. 5. Structural diagram of Yellow Fever virus (Emerging Human Viral Diseases).
| Catalog No. | Product Name | Applications |
|---|---|---|
| VK813034 | Anti-Yellow Fever Virus Envelope protein E Polyclonal Antibody | ELISA, IHC, WB |
| VK813031 | Recombinant Yellow Fever Virus Envelope protein E Protein, C-Fc | SDS-PAGE, WB, ELISA, Immunogen, Bioactivity testing in progress |
| VK813032 | Recombinant Yellow Fever Virus Envelope protein E Protein, N-His | SDS-PAGE, WB, ELISA, Immunogen, Bioactivity testing in progress |
| VK813041 | Recombinant Yellow Fever Virus Envelope protein E Protein, C-His | SDS-PAGE, WB, ELISA, Immunogen, Bioactivity testing in progress |
Note: Only four products are available for Yellow Fever in our catalog.
How It Works
- Envelope (E) Protein: Targets liver cells, causing jaundice and severe organ damage.
- NS4B Protein: Helps the virus dodge immune responses, spreading infection.
- NS5 Protein: Boosts viral replication, leading to high viral loads.
Zika: The Congenital Threat That Redefined Viral Surveillance
Zika virus (ZIKV), a flavivirus closely related to Dengue and West Nile, is primarily transmitted by Aedes mosquitoes, but also spreads via sexual contact and vertical transmission. Its unique neurotropism has been linked to fetal brain malformations, most notably microcephaly. ZIKV became a public health emergency in 2015–2016 following its explosive spread across the Americas. Though often asymptomatic in adults, its risks during pregnancy are severe.
Fig. 6. Structural diagram of Zika virus (doi.org/10.3389/fphar.2024.1418516).
| Catalog No. | Product Name | Applications |
|---|---|---|
| VK656010 | InVivoMAb Anti-ZIKV/DENV NS1c Antibody (1G5) | Blocking, ELISA |
| VK740013 | Anti-ZIKV Envelope protein E/DIII domain Antibody (Z004) | ELISA, FCM |
| VK656011 | Recombinant Zika Virus NS1 Protein, C-His | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| VK740011 | Recombinant ZIKV Envelope protein E Protein, C-His | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| VK498012 | Recombinant ZIKV Protein prM/prM Protein, N-GST & C-His | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
How It Works
- Envelope (E) Protein, DIII Domain: Attacks fetal brain cells, critical for neutralization and vaccine development.
- NS1 Protein: Enables placental transmission, linked to severe fetal complications.
- NS5 Protein: Targets neural cells, driving persistent infection in the fetal brain.
Japanese Encephalitis: Asia’s Neuroinvasive Menace
Japanese Encephalitis Virus (JEV) is a neurotropic flavivirus endemic to Asia and the Western Pacific. Transmitted by Culex mosquitoes, JEV causes severe brain inflammation with high fatality and neurological sequelae. While vaccines exist, they are not universally accessible in rural or low-income regions, creating a demand for improved diagnostics and transmission modeling.
Fig. 7. Structural diagram of Japanese Encephalitis virus (Nature Reviews Neurology volume 14, pages 298–313 (2018)).
| Catalog No. | Product Name | Applications |
|---|---|---|
| VK731010 | InVivoMAb Anti-JEV Envelope protein E Antibody (2F2) | ELISA, Neutralization, SPR |
| VK489014 | Anti-JEV NS1/Non-structural protein 1 Polyclonal Antibody | ELISA, IHC, WB |
| VK489011 | Recombinant JEV NS1 Protein, C-Fc | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| VK731022 | Recombinant JEV Envelope protein E Protein, N-His | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| VK611022 | Recombinant JEV Peptide pr Protein, N-GST & C-His | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
How It Works
- Envelope (E) Protein: Drives neuroinvasion and serves as the main target for vaccines.
- NS1 Protein: Aids in diagnostics and helps the virus evade immune detection.
- NS3/NS5 Proteins: Fuel viral replication and suppress immune responses.
Key Insight: Targeting key viral proteins like glycoproteins and non-structural proteins unlocks new paths for diagnostics, therapies, and vaccines to combat these relentless diseases.
Fig. 8. How these viruses move from mosquitoes to humans (10.1016/j.jobb.2023.12.003).
Why These Diseases Are Hard to Stop
Climate change, urban sprawl, and global travel are giving mosquitoes free rein to spread these viruses, making control a daunting challenge. Here’s why they’re so tough to tackle:
- Limited Treatments: Most rely on symptom relief, like paracetamol, with no targeted antiviral drugs.
- Few Vaccines: Only Yellow Fever, Dengue, and Japanese Encephalitis have vaccines, with access or efficacy issues persisting.
- Diagnostic Challenges: Overlapping symptoms among viruses like Dengue, Zika, and Chikungunya complicate accurate diagnosis without tools like RT-PCR.
- Mosquito Control Struggles: Insecticide resistance and inconsistent control efforts let mosquito populations thrive.
What’s Next for Fighting These Diseases
The battle against mosquito-borne diseases is heating up with innovative strategies. Scientists are exploring Wolbachia-infected or genetically modified mosquitoes to disrupt viral transmission, using tools like our AT554107 Wolbachia Detection Kit for PCR-based validation. Promising antivirals, such as ivermectin for flaviviruses or flavonoids like Delphinidin, show potential against Dengue, Zika, and Chikungunya, but require rigorous lab testing. New vaccine platforms depend on tools to evaluate immune responses and cross-reactivity, while rapid diagnostics like nanobiosensors and RT-PCR enable quick identification of co-circulating viruses. Meanwhile, GIS and molecular surveillance are helping predict outbreaks and track mosquito populations, giving public health teams a critical edge.
Need datasheets or more details? Contact us at support@abinscience.com.
Wrapping Up
Mosquitoes like Aedes and Culex are relentless, spreading viruses that challenge global health at every turn. By targeting their key proteins, researchers are forging new paths to diagnose, treat, and prevent these infections. abinScience’s lab-tested tools are empowering scientists to fight back, one breakthrough at a time.
Insights and figures drawn from: Higuera, A., & Ramírez, J. D. (2019). Molecular epidemiology of dengue, yellow fever, Zika, and chikungunya arboviruses: An update. Acta Tropica. Read the study.
